

# Expression of some resistant genes on six *Elizabethkingia* spp. strains isolated in Vietnam

Hieu Duc Nguyen<sup>1</sup>, Son Thai Nguyen<sup>3</sup>, Van Thi Thu Ha<sup>3</sup>, Minh Ngoc Nghiem<sup>1,2</sup>  
and Thuy Thi Bich Vo<sup>1,2\*</sup>

<sup>1</sup>Institute of Genome Research, Vietnam Academy of Science and Technology, Hanoi, 10000, Vietnam.

<sup>2</sup>Graduate University of Science and Technology, Vietnam Academy of Science and Technology, 10000, Hanoi, Vietnam.

<sup>3</sup>Department of Medical Microbiology, Military Hospital 103, Vietnam Medical Military University, Hanoi, 10000, Vietnam.

\*Corresponding author. Email: [thuytbvo@igr.ac.vn](mailto:thuytbvo@igr.ac.vn); [thuytbvo.igr@gmail.com](mailto:thuytbvo.igr@gmail.com)

Copyright © 2020 Nguyen et al. This article remains permanently open access under the terms of the [Creative Commons Attribution License 4.0](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received 17th March, 2020; Accepted 22nd April, 2020

**ABSTRACT:** This study focused on the assessment of the multiantibiotic-resistance and gene expression associated with multi-drug resistance in *Elizabethkingia*. Six *Elizabethkingia* spp. strains were isolated from patient samples, and the antibiotic-resistance of the six isolates with all 14 tested antibiotics was confirmed. MacConkey subculture and 16S rRNA sequencing were used to identify the six isolates as; one *Elizabethkingia meningoseptica* (*E. meningoseptica*) isolate, and five *E. anophelis* isolates. Seven genes including four-resistant genes (*blaB*, *blaCME*, *ant6*, *lolD* and *catB* and two antibiotics target gene (*gyrA* and *parC*) were selected for evaluation of gene expression using Reverse Transcriptase PCR (RT-PCR). The resistant genotype–phenotype correlation of  $\beta$ -lactams (*blaB* and *blaCME*) and fluoroquinolones (*gyrA* and *parC*) groups was observed. The chloramphenicol resistant gene (*catB*) was also found in all six isolates. The gene expression level was different between isolates but lacked the relationship with high resistant phenotypes. The aminoglycoside (*ant6*) and macrolide (*lolD*) resistant genes were absent, which indicated that other genetic factors could be implicated. The multidrug-resistance of *Elizabethkingia* spp. is reported for the first time in Vietnam, demonstrating the presence of this drug-resistance bacterium in the Vietnamese hospital environment. The initial results in this study will be the basis for further research regarding *Elizabethkingia* spp.

**Keywords:** 16S rRNA, *Elizabethkingia* spp, multi-antimicrobial resistance, phylogeny, resistant gene expression, Reverse Transcriptase PCR.

**Abbreviation:** RT-PCR, Reverse Transcriptase PCR; CLSI, Clinical and Laboratory Standards Institute; cDNA, complementary DNA; MUSCLE, Multiple Sequence Comparison by Log-Expectation; ANOVA, Analysis of variance; MIC, minimum inhibitory concentration.

## INTRODUCTION

*Elizabethkingia* is Gram-negative, non-motile, aerobic, catalase positive, oxidase positive, and indole positive bacteria bacilli (Janda and Lopez, 2017). There are three species: *E. meningoseptica*, *E. miricola*, and *E. anophelis* that are known to infect humans (Jean et al., 2014) and are the cause of many outbreaks in the United States (Perrin et al., 2017), Taiwan (Lin et al., 2018), and Hong Kong (Lau et al., 2016). They can be located in water, soil and especially on hospital surfaces (Weaver et al., 2010).

*Elizabethkingia* spp. is opportunistic bacteria and cause pneumonia, sepsis, meningitis, and fever, and can threaten the survival of infants and immunodeficient patients (Breurec et al., 2016; Lau et al., 2016). The treatment of *Elizabethkingia* spp. is challenging because of the resistance to multiple antibiotics, such as  $\beta$ -lactam, aminoglycosides, tetracyclines, and chloramphenicol, which are the most common antibiotics for Gram negative bacteria (Kirby et al., 2004). However, they showed

susceptibility to treatment with the antibiotics for Gram-Positive Bacteria (Ceyhan and Celik, 2011).

*Elizabethkingia* spp. are often resistant to  $\beta$ -lactam antibiotics due to class A extended-spectrum  $\beta$ -lactamases and class B metallo- $\beta$ -lactamases (Lin et al., 2012). In recent years, reference genomes of *Elizabethkingia* spp. were analyzed and published in different countries. Many antibiotic-resistant genes were reported in all of the three species related to  $\beta$ -lactam, sulfonamide, tetracycline, macrolide, quinolone, aminoglycoside, and chloramphenicol (Chen et al., 2017; Wang et al., 2019). These studies showed the variety of genes related to antibiotic-resistance, and they can be reason for the different in susceptibility test results of published isolates (Lin et al., 2019).

In Vietnam, the understanding of the antibiotic-resistance of *Elizabethkingia* has been limited. There was not any research about *Elizabethkingia* and their resistant characteristics. Therefore, in this study, multiple antibiotic resistant *Elizabethkingia* isolates in a Vietnam hospital and screened for resistant genes were detected. However, because the previous database in Vietnam was lacked, the genes was selected from published resistant genes of *Elizabethkingia* (Chen et al., 2017; González and Vila, 2012; Jian et al., 2018). The *blaB* and *blaCME* genes were two of the  $\beta$ -lactamases family. In which, the *blaB* gene encodes carbapenemases enzymes (enzymes that catalyze the degradation of the carbapenem group) (Vessillier et al., 2002), while the CME enzyme encoded by *blaCME* is capable of hydrolyzing cephalosporin, including fourth-generation cephalosporin (Bellais et al., 2000). The *catB* gene encoded for Chloramphenicol acetyltransferase (CAT) enzymes. These enzymes play a role in chloramphenicol acetylation through the use of acetyl coenzyme A (Rogers et al., 2002). Both *gyrA* and *parC* were genes encoding enzymes regarded the targets for quinolones antibiotics and maintained quinolone-resistance-determining region (Fàbrega et al., 2009; Nouri et al., 2016). The *ant6* and *ants* family encoded for the Nucleoside triphosphate-dependent O-phosphotransferases that catalyzed the phosphorylation, one of the most common mechanisms of aminoglycoside inactivation (Ramirez and Tolmasky, 2010). Even the expression of *loID*, a macrolide resistance gene in the Gram-positive antibiotic group, also presented in many published isolates (Chen et al., 2017).

Thus, the objective of this study is to assess the multi-antibiotic-resistance and gene expression associated with multidrug-resistance in *Elizabethkingia*. The results of this test are going to lay the groundwork for further research concerning *Elizabethkingia* in Vietnam.

## MATERIALS AND METHODS

### Bacterial isolates

Six multiple antibiotic-resistant isolates of *Elizabethkingia*

spp. were isolated from sputum, bronchial fluid, and blood samples during 2017 and stored in the Vietnam Military Medical Academy (Table 1) before this study was performed. The VITEK2 system (bioMérieux Vitek; bioMérieux, Marcy l'Etoile, France) was used to identify them as *Elizabethkingia* species and confirmed the antimicrobial susceptibility using MIC standards ( $\mu\text{g/mL}$ ) for other non-*Enterobacteriaceae* in the Clinical and Laboratory Standards Institute (CLSI) guideline (Patel et al., 2017). The antimicrobial susceptibilities were tested for 14 different antibiotics.

### Species identification

Six isolates were subcultured on MacConkey agar plates and incubated at  $37^{\circ}\text{C} \pm 1^{\circ}\text{C}$  for  $18 \text{ h} \pm 2 \text{ h}$ . The subculture results were confirmed using *16S rRNA* gene phylogenetic analysis. The *16S rRNA* gene of six isolates was sequenced in the ABI3500 system (Applied Biosystem, United States). The six isolate sequences in this study, and 18 published reference sequences including three *Elizabethkingia* and 15 other *Flavobacteriaceae* isolates were aligned using MUSCLE algorithms. The maximum likelihood tree with T92+G substitution model and bootstrap 1000 were built to determine the genetic relationship. All analysis processes were performed using MEGA6 software (Tamura et al., 2013).

### RNA extraction

Total RNA was extracted using the TRIZOL RNA Isolation Protocol. RNA concentrations were determined using a NanoDrop™ One Microvolume UV-Vis spectrophotometer (Thermo Fisher Scientific, United States) and diluted to a final concentration of  $1 \mu\text{g}/\mu\text{l}$ .

### Resistant gene expression screening using RT-PCR

cDNA synthesis was performed according to the Revert Aid First Strand cDNA Synthesis Kit manual (Thermo Fisher Scientific, San Jose, CA, US) with  $1 \mu\text{l}$  of total RNA in a  $20 \mu\text{l}$  reaction volume. One  $\mu\text{l}$  of cDNA was continuously used as template for  $25 \mu\text{l}$  PCR reaction containing  $12.5 \mu\text{l}$  Thermo Scientific DreamTaq PCR Master Mix (Thermo Fisher Scientific, San Jose, CA, US),  $0.5 \mu\text{l}$  of each  $10 \text{ pmol}/\mu\text{l}$  primer, and  $10.5 \mu\text{l}$  of nuclease free water.

All reactions were performed in triplicate with PCR conditions of  $95^{\circ}\text{C}$  for 5 min, followed by 25 to 40 cycles of denaturation at  $95^{\circ}\text{C}$  for 30 seconds, annealing of specific primers for 30 seconds, and extension at  $72^{\circ}\text{C}$  for 1 min. The reaction finished at  $72^{\circ}\text{C}$  for 7 min and was finally held at  $4^{\circ}\text{C}$ . The primers and annealing temperatures for the amplification of seven resistant genes and the *16S rRNA* gene are listed in Table 2. The gel electrophoresis results

**Table 1.** Name and sample sources of six multidrug-resistant *Elizabethkingia* strains.

Strains	Sample sources	MacConkey subculture
17 -13 M	Sputum	No-growth
17 -28D	Bronchial fluid	No-growth
17 -30M	Blood	No-growth
17 -35D	Bronchial fluid	No-growth
17 -84M	Blood	Growth
17 -88M	Blood	No-growth

**Table 2.** A list of primer pairs was used in this study.

No.	Primer	Sequence	Size (bp)	Tm (°C)	Reference
1	16S <i>rRNA</i>	Fw GCCTACGGGAGGCAGCAG	550	50	
		Rv CCGTCAATTCMTTGTGATTT			
2	<i>blaB</i>	Fw TTGTGGTTATAGACTGTCCGTGGG	136	55	(González & Vila, 2012)
		Rv TATCAAGACCTCCGGCACGAT			
3	<i>blaCME</i>	Fw AAGAAAGCCACAGTAGCTGTTTC	695	55	(González & Vila, 2012)
		Rv ACTGCAATTGCATAATGTTTACC			
4	<i>catB</i>	Fw CCCC GGATTCTTTCTCGGAT	338	55	NUHP1 (NZ_CP007547.1)
		Rv AAGTCCTGTTTTT GCCACCG			
5	<i>parC</i>	Fw GCTCAGTATGGCAATGCTAAAA	785	50	(Jian <i>et al.</i> , 2018)
		Rv TTGCTCTTACCTTACCGCCG			
6	<i>gyrA</i>	Fw AGCCCGTTGTTTAAATCCTGAA	743	50	(Jian <i>et al.</i> , 2018)
		Rv CCCTGTTGGGAAGTCTGGTG			
7	<i>ant6</i>	Fw GAAAGAGGCGCAACGGGATA	202	50	NUHP1 (NZ_CP007547.1)
		Rv GCGGGCAAGACATTTTACCA			
8	<i>lolD</i>	Fw GAGCTTGCAGGAGTTCCGAT	333	50	NUHP1 (NZ_CP007547.1)
		Rv GTCTAATGCTCCGGTTGGCT			

were analyzed using the Quantity One program (Gel Doc EQ; Bio-Rad, Hercules, CA, US). The resistant gene expression level was normalized to the level of the 16S *rRNA* gene.

**Statistical analyses**

Gene expression statistical comparison was performed using ANOVA one-way test in GraphPad Prism version 5 (GraphPad Software Inc., La Jolla, CA, US). A p-value of ≤ 0.05 was considered statistically significant.

**RESULTS AND DISCUSSION**

**Susceptibility test**

Six *Elizabethkingia* spp. isolates were tested with 14

antibiotics from nine groups. The antimicrobial susceptibility test mentioned that the multidrug-resistance appeared in six *Elizabethkingia* spp. isolates. All of the tested antibiotics were very common and widely used in the treatment of infection. Including the broad-spectrum antibiotics such as ciprofloxacin and levofloxacin, two of the most widely used antibiotics, were effective against both Gram-negative and Gram-positive bacteria (Fàbrega *et al.*, 2009; Heeb *et al.*, 2011), and trimethoprim/sulfamethoxazole, which was a potential candidate for *Elizabethkingia* treatment (Gokce *et al.*, 2012). After all, ciprofloxacin and levofloxacin were resistant by five of isolates (excepted 17-88M), while trimethoprim/sulfamethoxazole also produced a resistant result in the 17-13M and 17-35D isolates and an intermediate result in the other four isolates (Table 3). These resistant phenotypes were similar with previous researches (Lin *et al.*, 2019), even Piperacillin and Piperacillin/Tazobactam,

**Table 3.** Summary of susceptibility test.

Antibiotics	Groups	Susceptible (MIC Breakpoints)	Intermediate	Resistant (MIC Breakpoints)
AN-Amikacin	Amino-glycosides	0 ( $\leq 16$ $\mu\text{g/mL}$ )	0	6 ( $\geq 64$ $\mu\text{g/mL}$ )
GM-Gentamicin		0 ( $\leq 4$ $\mu\text{g/mL}$ )	0	6 ( $\geq 16$ $\mu\text{g/mL}$ )
TM-Tobramycin		0 ( $\leq 4$ $\mu\text{g/mL}$ )	0	6 ( $\geq 16$ $\mu\text{g/mL}$ )
TCC-Ticarcillin/Clavulanic Acid	Beta-lactams	0 ( $\leq 16$ $\mu\text{g/mL}$ )	0	6 ( $\geq 128$ $\mu\text{g/mL}$ )
TIC-Ticarcillin		0 ( $\leq 16$ $\mu\text{g/mL}$ )	0	6 ( $\geq 128$ $\mu\text{g/mL}$ )
TZP-Piperacillin/Tazobactam		0 ( $\leq 16$ $\mu\text{g/mL}$ )	0	6 ( $\geq 128$ $\mu\text{g/mL}$ )
ATM-Aztreonam	Monobactams	0 ( $\leq 8$ $\mu\text{g/mL}$ )	0	6 ( $\geq 32$ $\mu\text{g/mL}$ )
IPM-Imipenem	Carbapenems	0 ( $\leq 4$ $\mu\text{g/mL}$ )	0	6 ( $\geq 16$ $\mu\text{g/mL}$ )
MEM-Meropenem		0 ( $\leq 4$ $\mu\text{g/mL}$ )	0	6 ( $\geq 16$ $\mu\text{g/mL}$ )
CAZ-Ceftazidime	Cephems (parenteral)	0 ( $\leq 8$ $\mu\text{g/mL}$ )	0	6 ( $\geq 32$ $\mu\text{g/mL}$ )
FEP-Cefepime		0 ( $\leq 8$ $\mu\text{g/mL}$ )	0	6 ( $\geq 32$ $\mu\text{g/mL}$ )
PIP-Piperacillin	Penicillins	0 ( $\leq 16$ $\mu\text{g/mL}$ )	0	6 ( $\geq 128$ $\mu\text{g/mL}$ )
CIP-Ciprofloxacin	Fluoroquinolones	0 ( $\leq 1$ $\mu\text{g/mL}$ )	1	5 ( $\geq 4$ $\mu\text{g/mL}$ )
LEV-Levofloxacin		0 ( $\leq 2$ $\mu\text{g/mL}$ )	1	5 ( $\geq 8$ $\mu\text{g/mL}$ )
SXT-Trimethoprim/ Sulfamethoxazole	Folate pathway inhibitors	0 ( $\leq 4$ $\mu\text{g/mL}$ )	4	2 ( $\geq 16$ $\mu\text{g/mL}$ )
CS-Colistin	Lipopeptides	0 ( $\leq 2$ $\mu\text{g/mL}$ )	0	6 ( $\geq 4$ $\mu\text{g/mL}$ )

which most published isolates were susceptible to, also observed the resistance in this study. This is a warning concerning the emergency status of resistance in Vietnam's environmental hospitals. The frequent use and misuse of antibiotics have led to the emergence of multidrug-resistant bacteria.

### Species identification


Following the previous study, the *16S rRNA* sequence-based method to determine the species of each isolate was selected (Han et al., 2017). Based on the *16S rRNA* sequences, the phylogenetic tree showed the different genetic between 3 groups of the *Flavobacteriaceae* family. Six isolates in this study belonged to the *Elizabethkingia* groups as supported by 90 bootstrap percentage, and had a closer relationship with *E. meningoseptica* and *E. anophelis* than *E. miricola* (Figure 1). Unfortunately, the sequence similarity of our strains *16S rRNA* with public sequences to be: *E. miricola* (98.8-99%), *E. meningoseptica* (99.2-99.4%) and *E. anophelis* (99.6-99.8%) (data not shown) decreased the bootstrap percentage to less than 70%, which is the supported level for species determination (Soltis and Soltis, 2003). Hence,

the MacConkey subculture method was used as the parallel approach, based on the *E. anophelis* phenotype characteristic that lacks growth in MacConkey medium (Kämpfer et al., 2011).

After 18 hours of cultivation, only the developing of 17-84M on MacConkey agar petri was observed, similar to the phenotype characteristic of *E. meningoseptica* (Ratnamani and Rao, 2013), and *E. miricola* (Gupta et al., 2017). And 17-84M isolate was closer to *E. meningoseptica* than *E. miricola* in the phylogenetic tree, so it was concluded that 17-84M isolate was *E. meningoseptica*. Five other strains cannot grow in MacConkey medium and were close with *E. anophelis* in the phylogenetic tree, so it was concluded that they were *E. anophelis*. The *16S rRNA* sequences of the 17-13M, 17-28D, 17-30M, 17-35D, 17-84M, and 17-88M isolates were published with GenBank accession number MK156744, MK156750, MK156754, MK156757, MK156761, and MK156765 respectively.

### Resistant gene expression screening using RT-PCR

Seven selected genes were recommended in many previous articles that are related to the resistance of *Elizabethkingia* spp. (Chen et al., 2017; González and Vila,




**Figure 1.** Phylogenetic tree was built using Maximum-Likelihood algorithm, bootstrap 1000. ▲: six Vietnam multidrug-resistance *Elizabethkingia* strains.

2012; Jian et al., 2018) were selected to test the expression in the six isolates (Table 4). Besides, because of this commonality in previously published articles, *lolD* and *catB* were selected to test the gene expression without having results from the previous susceptibility test.

In the other five genes expressed, the result showed the similarities between resistant phenotype and genotype and indicated those genes relate to the resistance of *Elizabethkingia*. It was surprising that two genes; *ant6* and *lolD* were absent in all isolates, that make the difference of genotype between these isolates and published isolates (Chen et al., 2017; Jian et al., 2018). All the more, the expression levels of five genes were different for each. Some hypotheses suggest that the drug-resistant phenotype of multidrug-resistant bacteria can be predicted by the change in expression of a small number of genes (Ferrer et al., 2017). In this study, there was a bias of high expression in 17-84M, the only isolated *E. meningoseptica* strain in four out of five genes, except for the *parC* gene

showed the highest expression in the 17-88M isolate. The 17-13M and 17-28D isolates seem to be weaker gene expression isolates than the other, even though 17-88M isolate also showed the lowest *catB* gene expression level (35.9% gene expression of 17-88M strain) (Figure 2). However, there was not a clear relationship between the gene expression and the high resistant phenotype. Thus, it was very hard to confirm the role of these genes to the resistant phenotype of *Elizabethkingia*.

The explanation for this result may come from the regulation of other genetic factors related to antibiotic-resistance. There are many different signaling pathways also relate to the linking mechanism between the genotype and phenotype of drug-resistant in bacteria (van Hoek et al., 2011). Therefore, the absence of aminoglycoside (*ant6*) and macrolide (*lolD*) resistant genes can be replaced by another factor. Some mutation genes also play a role in the complex relationship of genotypes to drug-resistant phenotypes. Many different types of mutations can cause



**Figure 2.** Expression of five multidrug-resistance related genes. ANOVA one-way was performed to compare the expression between the highest expression strain (▲) and the other strains. \* p < 0.05; \*\* p < 0.01; \*\*\* p < 0.001.

the same resistant phenotype and also cause the change of many different phenotypes that affect the resistance and sensitivity to many antibiotics (Toprak et al., 2012).

Previous studies have shown that a large number of mutant genes affect susceptibility and antibiotic-resistance, including genes that are not directly related to known drug-

**Table 4.** Antibiotic resistant genes among *Elizabethkingia* strains.

Groups	Gene	17-13M	17-28D	17-30M	17-35D	17-84M	17-88M
Beta-lactams	<i>blaB</i>	+	+	+	+	+	+
	<i>blaCME</i>	+	+	+	+	+	+
Quinolones	<i>gyrA</i>	+	+	+	+	+	+
	<i>parC</i>	+	+	+	+	+	+
Amino-glycosides	<i>ant6</i>	-	-	-	-	-	-
Chloramphenicol	<i>catB</i>	+	+	+	+	+	+
Macrolide	<i>lolD</i>	-	-	-	-	-	-

resistance in bacteria. Overall, the complex relationship between drug-resistance, genetic changes, and phenotypic changes remains unclear (Ferrer et al., 2017). Therefore, the combination of gene expression and gene sequencing analysis allows us to understand major phenotypic changes that produce drug-resistance. To get the conclusions, comprehensive screening tests for all relevant genes should be conducted for other resistances that appear on multidrug-resistant isolates in Vietnam.

On the other hand, the emergence of multidrug-resistant opportunistic strains from hospital environment such as *Elizabethkingia* is still a serious concern. Besides being difficult for treatment, the drug-resistant phenotype of *Elizabethkingia* can be transmitted to other microorganism isolates through horizontal gene transfer. Antibiotic sensitive isolates received the resistant genes can become resistant isolates (Brown-Jaque et al., 2015). Antibiotic-resistance is an important issue for public health, and the control of drug-resistant bacteria from different environments is an important part of any country's strategy for preventing drug-resistant bacteria. This study showed the status of drug-resistance of several bacteria found in the hospital environment, and the necessity of further research to understand the mechanism of drug-resistance and to find effective treatments for *Elizabethkingia*.

## Conclusions

In conclusion, the multidrug-resistance of *Elizabethkingia* spp. was reported for the first time in Vietnam, showing the status of drug-resistance of bacteria in the Vietnam's hospital environment. The species identification mentioned the circulation of both *E. meningoseptica* and *E. anophelis* in Vietnam. The result also showed the genotype–phenotype correlation of  $\beta$ -lactams (*blab* and *blaCME*) and fluoroquinolones (*gyrA* and *parC*) resistance. But the expression level was not commensurate with the high resistant phenotype and the absence of aminoglycoside (*ant6*) and macrolide (*lolD*) resistant genes indicate that other genetic factors could be implicated. Therefore, further research is required to

confirm the resistant genes and may be the molecular marker for antibiotic-resistance *Elizabethkingia* detection.

## COMPLIANCE WITH ETHICAL STANDARDS

Not applicable. The study was based on laboratory work performed with screening strains isolated from human. No data from human patient research was used.

## COMPETING INTERESTS

The authors declare that they have no conflict of interests.

## ACKNOWLEDGEMENTS

This research is funded by the Vietnam Academy of Science and Technology under grant number NCVCC40.03/19-19. The authors would like to thank colleagues at the Military Hospital 103, Vietnam Military Medical University, for supplying samples.

## REFERENCES

- Bellais, S., Poirel, L., Naas, T., Girlich, D., & Nordmann, P. (2000). Genetic-biochemical analysis and distribution of the Ambler class A  $\beta$ -lactamase CME-2, responsible for extended-spectrum cephalosporin resistance in *Chryseobacterium* (*Flavobacterium*) *meningosepticum*. *Antimicrobial Agents and Chemotherapy*, 44(1), 1-9.
- Breurec, S., Criscuolo, A., Diancourt, L., Rendueles, O., Vandenbergert, M., Passet, V., Caro, V., Rocha, E. P., Touchon, M., & Brisse, S. (2016). Genomic epidemiology and global diversity of the emerging bacterial pathogen *Elizabethkingia anophelis*. *Scientific Reports*, 6, 30379.
- Brown-Jaque, M., Calero-Cáceres, W., & Muniesa, M. (2015). Transfer of antibiotic-resistance genes via phage-related mobile elements. *Plasmid*, 79, 1-7.
- Ceyhan, M., & Celik, M. (2011). *Elizabethkingia meningosepticum* (*Chryseobacterium meningosepticum*) infections in children. *International Journal of Pediatrics*, Volume 2011, Article ID 215237, 7 pages.
- Chen, S., Soehnen, M., Downes, F. P., & Walker, E. D. (2017).

- Insights from the draft genome into the pathogenicity of a clinical isolate of *Elizabethkingia meningoseptica* Em3. *Standards in genomic sciences*, 12, Article number 56.
- Fàbrega, A., Madurga, S., Giral, E., & Vila, J. (2009). Mechanism of action of and resistance to quinolones. *Microbial Biotechnology*, 2(1), 40-61.
- Ferrer, M., Méndez-García, C., Rojo, D., Barbas, C., & Moya, A. (2017). Antibiotic use and microbiome function. *Biochemical Pharmacology*, 134, 114-126.
- Gokce, I. K., Oncel, M. Y., Ozdemir, R., Erdeve, O., Oguz, S. S., Canpolat, F. E., ... & Dilmen, U. (2012). Trimethoprim-sulfamethoxazole treatment for meningitis owing to multidrug-resistant *Elizabethkingia meningoseptica* in an extremely low-birthweight, premature infant. *Paediatrics and International Child Health*, 32(3), 177-179.
- González, L. J., & Vila, A. J. (2012). Carbapenem resistance in *Elizabethkingia meningoseptica* is mediated by metallo- $\beta$ -lactamase *blaB*. *Antimicrobial Agents and Chemotherapy*, 56(4), 1686-1692.
- Gupta, P., Zaman, K., Mohan, B., & Taneja, N. (2017). *Elizabethkingia miricola*: A rare non-fermenter causing urinary tract infection. *World Journal of Clinical Cases*, 5(5), 187-190.
- Han, M. S., Kim, H., Lee, Y., Kim, M., Ku, N. S., Choi, J. Y., Yong, D., Jeong, S. H., Lee, K., & Chong, Y. (2017). Relative prevalence and antimicrobial susceptibility of clinical isolates of *Elizabethkingia* species based on 16S rRNA gene sequencing. *Journal of Clinical Microbiology*, 55(1), 274-280.
- Heeb, S., Fletcher, M. P., Chhabra, S. R., Diggle, S. P., Williams, P., & Cámara, M. (2011). Quinolones: from antibiotics to autoinducers. *FEMS Microbiology Reviews*, 35(2), 247-274.
- Janda, J. M., & Lopez, D. L. (2017). Mini review: new pathogen profiles: *Elizabethkingia anophelis*. *Diagnostic Microbiology and Infectious Disease*, 88(2), 201-205.
- Jean, S. S., Lee, W. S., Chen, F. L., Ou, T. Y., & Hsueh, P. R. (2014). *Elizabethkingia meningoseptica*: an important emerging pathogen causing healthcare-associated infections. *Journal of Hospital Infection*, 86(4), 244-249.
- Jian, M. J., Cheng, Y. H., Perng, C. L., & Shang, H. S. (2018). Molecular typing and profiling of topoisomerase mutations causing resistance to ciprofloxacin and levofloxacin in *Elizabethkingia* species. *PeerJ*, 6, e5608.
- Kämpfer, P., Matthews, H., Glaeser, S. P., Martin, K., Lidders, N., & Faye, I. (2011). *Elizabethkingia anophelis* sp. nov., isolated from the midgut of the mosquito *Anopheles gambiae*. *International Journal of Systematic and Evolutionary Microbiology*, 61(11), 2670-2675.
- Kirby, J. T., Sader, H. S., Walsh, T. R., & Jones, R. N. (2004). Antimicrobial susceptibility and epidemiology of a worldwide collection of *Chryseobacterium* spp.: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). *Journal of Clinical Microbiology*, 42(1), 445-448.
- Lau, S. K., Chow, W. N., Foo, C. H., Curreem, S. O., Lo, G. C. S., Teng, J. L., Chen, J. H., Ng, R. H., Wu, A. K., Cheung, I. Y., & Chau, S. K. (2016). *Elizabethkingia anophelis* bacteremia is associated with clinically significant infections and high mortality. *Scientific Reports*, 6, Article number 26045.
- Lin, J. N., Lai, C. H., Yang, C. H., & Huang, Y. H. (2019). *Elizabethkingia* infections in humans: from genomics to clinics. *Microorganisms*, 7(9), 295.
- Lin, J. N., Lai, C. H., Yang, C. H., Huang, Y. H., & Lin, H. H. (2018). Clinical manifestations, molecular characteristics, antimicrobial susceptibility patterns and contributions of target gene mutation to fluoroquinolone resistance in *Elizabethkingia anophelis*. *Journal of Antimicrobial Chemotherapy*, 73(9), 2497-2502.
- Lin, X. H., Xu, Y. H., Sun, X. H., Huang, Y., & Li, J. B. (2012). Genetic diversity analyses of antimicrobial resistance genes in clinical *Chryseobacterium meningosepticum* isolated from Hefei, China. *International Journal of Antimicrobial Agents* (Print), 40(2), 186-188.
- Nouri, R., Ahangarzadeh Rezaee, M., Hasani, A., Aghazadeh, M., & Asgharzadeh, M. (2016). The role of *gyrA* and *parC* mutations in fluoroquinolones-resistant *Pseudomonas aeruginosa* isolates from Iran. *Brazilian Journal of Microbiology*, 47(4), 925-930.
- Patel, J. B., Cockerill III, F., Eliopoulos, G., Jenkins, S., Lewis, J., Limbago, B., & Nicolau, D. (2017). M100 Performance standards for antimicrobial susceptibility testing. *United State: Clinical and Laboratory Standards Institute*, 240.
- Perrin, A., Larssonneur, E., Nicholson, A. C., Edwards, D. J., Gundlach, K. M., Whitney, A. M., Gulvik, C. A., Bell, M. E., Rendueles, O., Cury, J., & Hugon, P. (2017). Evolutionary dynamics and genomic features of the *Elizabethkingia anophelis* 2015 to 2016 Wisconsin outbreak strain. *Nature Communications*, 8, Article number 15483.
- Ramirez, M. S., & Tolmasky, M. E. (2010). Aminoglycoside modifying enzymes. *Drug Resistance Updates*, 13(6), 151-171.
- Ratnamani, M. S., & Rao, R. (2013). *Elizabethkingia meningoseptica*: emerging nosocomial pathogen in bedside hemodialysis patients. *Indian Journal of Critical Care Medicine*, 17(5), 304-307.
- Rogers, E. J., Rahman, M. S., Hill, R. T., & Lovett, P. S. (2002). The chloramphenicol-inducible *catB* gene in *Agrobacterium tumefaciens* is regulated by translation attenuation. *Journal of Bacteriology*, 184(15), 4296-4300.
- Soltis, P. S., & Soltis, D. E. (2003). Applying the bootstrap in phylogeny reconstruction. *Statistical Science*, 18(2), 256-267.
- Tamura, K., Stecher, G., Peterson, D., Filipiński, A., & Kumar, S. (2013). MEGA6: molecular evolutionary genetics analysis version 6.0. *Molecular Biology and Evolution*, 30(12), 2725-2729.
- Toprak, E., Veres, A., Michel, J. B., Chait, R., Hartl, D. L., & Kishony, R. (2012). Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. *Nature Genetics*, 44, 101-105.
- Van Hoek, A. H., Mevius, D., Guerra, B., Mullany, P., Roberts, A. P., & Aarts, H. J. (2011). Acquired antibiotic resistance genes: an overview. *Frontiers in Microbiology*, Volume 2, Article Number 203.
- Vessillier, S., Docquier, J. D., Rival, S., Frere, J. M., Galleni, M., Amicosante, G., Rossolini, G. M., & Franceschini, N. (2002). Overproduction and biochemical characterization of the *Chryseobacterium meningosepticum* BlaB metallo- $\beta$ -lactamase. *Antimicrobial agents and chemotherapy*, 46(6), 1921-1927.
- Wang, M., Gao, H., Lin, N., Zhang, Y., Huang, N., Walker, E. D., Ming, D., Chen, S., & Hu, S. (2019). The antibiotic resistance and pathogenicity of a multidrug-resistant *Elizabethkingia anophelis* isolate. *MicrobiologyOpen*, 8(11), e804.
- Weaver, K. N., Jones, R. C., Albright, R., Thomas, Y., Zambrano, C. H., Costello, M., Havel, J., Price, J., & Gerber, S. I. (2010). Acute emergence of *Elizabethkingia meningoseptica* infection among mechanically ventilated patients in a long-term acute care facility. *Infection Control and Hospital Epidemiology*, 31(1), 54-58.